Thus, the refinement of Ad vectors for TRAIL-based gene therapy continues, with the goal of increasing TRAIL transgene expression specifically in transformed tumor cells, thereby increasing the potential therapeutic benefits of this approach while simultaneously minimizing toxicity. The gene discussed is TNFSF10; the disease is neoplasm.